日本由ST81/SCC IV型耐甲氧西林、万古霉素中介菌引起的起搏器相关感染
Pacemaker-associated infection caused by ST81/SCC IV methicillin-resistant, vancomycin-intermediate in Japan.
作者信息
Sakurada M, Sumi H, Kaji K, Kobayashi N, Sakai Y, Aung M S, Urushibara N, Kobayashi N
机构信息
Department of Pharmacy, Sapporo Medical University School of Medicine, Sapporo, Japan.
Department of Laboratory, Sapporo Medical University School of Medicine, Sapporo, Japan.
出版信息
New Microbes New Infect. 2020 Feb 14;35:100656. doi: 10.1016/j.nmni.2020.100656. eCollection 2020 May.
Abstract
A 76-year-old Japanese man was admitted to hospital for treatment of fever and skin lesion at the implantation site of his pacemaker. During his hospitalization, vancomycin-intermediate (MIC 4 μg/mL) with reduced susceptibility to daptomycin was isolated from venous blood. This isolate was identified as methicillin-resistant with SCC IV and was genotyped as sequence type 81, VIIa and type t7044, harbouring (')-(″) and enterotoxin(-like) genes s and The patient was successfully treated with daptomycin, minocycline and sulfamethoxazole/trimethoprim. We describe the identification of sequence type 81/SCC IV vancomycin-intermediate from pacemaker-associated septicaemia.
摘要
一名76岁的日本男性因起搏器植入部位出现发热和皮肤病变入院治疗。住院期间，从静脉血中分离出对达托霉素敏感性降低的万古霉素中介株（MIC为4μg/mL）。该分离株被鉴定为具有IV型葡萄球菌盒式染色体（SCC）的耐甲氧西林菌株，基因分型为序列类型81、VIIa和t7044型，携带（'）-（″）和肠毒素（类）基因s和。患者接受达托霉素、米诺环素和磺胺甲恶唑/甲氧苄啶治疗成功。我们描述了从起搏器相关败血症中鉴定出序列类型81/SCC IV万古霉素中介株的过程。
相似文献
1
Pacemaker-associated infection caused by ST81/SCC IV methicillin-resistant, vancomycin-intermediate in Japan.
New Microbes New Infect. 2020 Feb 14;35:100656. doi: 10.1016/j.nmni.2020.100656. eCollection 2020 May.
2
Antimicrobial susceptibility and molecular characteristics of methicillin-resistant Staphylococcus aureus in a Japanese secondary care facility.
J Infect Chemother. 2016 Jan;22(1):14-8. doi: 10.1016/j.jiac.2015.08.011. Epub 2015 Nov 24.
3
Prevalence of vancomycin-intermediate Staphylococcus aureus (VISA) and heterogeneous VISA among methicillin-resistant S. aureus with high vancomycin minimal inhibitory concentrations in Taiwan: A multicenter surveillance study, 2012-2013.
J Microbiol Immunol Infect. 2016 Oct;49(5):701-707. doi: 10.1016/j.jmii.2015.07.003. Epub 2015 Jul 31.
4
Activity of ceftobiprole against methicillin-resistant Staphylococcus aureus strains with reduced susceptibility to daptomycin, linezolid or vancomycin, and strains with defined SCCmec types.
Int J Antimicrob Agents. 2014 Apr;43(4):323-7. doi: 10.1016/j.ijantimicag.2013.11.005. Epub 2013 Dec 11.
5
Clonal Diversity and Genetic Characteristics of Methicillin-Resistant Isolates from a Tertiary Care Hospital in Japan.
Microb Drug Resist. 2019 Oct;25(8):1164-1175. doi: 10.1089/mdr.2018.0468. Epub 2019 May 20.
6
Clinical and Microbiological Characteristics of Heteroresistant and Vancomycin-Intermediate Staphylococcus aureus from Bloodstream Infections in a Brazilian Teaching Hospital.
PLoS One. 2016 Aug 30;11(8):e0160506. doi: 10.1371/journal.pone.0160506. eCollection 2016.
7
Emergence of vancomycin-intermediate and -resistant Staphylococcus aureus among methicillin-resistant S. aureus isolated from clinical specimens in the northwest of Iran.
J Glob Antimicrob Resist. 2018 Sep;14:4-9. doi: 10.1016/j.jgar.2018.01.017. Epub 2018 Feb 14.
8
In vivo development of daptomycin resistance in vancomycin-susceptible methicillin-resistant Staphylococcus aureus severe infections previously treated with glycopeptides.
Eur J Clin Microbiol Infect Dis. 2016 Apr;35(4):625-31. doi: 10.1007/s10096-016-2581-4. Epub 2016 Jan 27.
9
Antibiotic susceptibility survey of blood-borne MRSA isolates in Japan from 2008 through 2011.
J Infect Chemother. 2014 Sep;20(9):527-34. doi: 10.1016/j.jiac.2014.06.012. Epub 2014 Jul 22.
10
Telavancin demonstrates activity against methicillin-resistant Staphylococcus aureus isolates with reduced susceptibility to vancomycin, daptomycin, and linezolid in broth microdilution MIC and one-compartment pharmacokinetic/pharmacodynamic models.
Antimicrob Agents Chemother. 2015 Sep;59(9):5529-34. doi: 10.1128/AAC.00773-15. Epub 2015 Jun 29.
引用本文的文献
1
Molecular Mechanisms of Drug Resistance in .
Int J Mol Sci. 2022 Jul 22;23(15):8088. doi: 10.3390/ijms23158088.
2
Teicoplanin combined with conventional vancomycin therapy for the treatment of pulmonary methicillin-resistant and infections.
World J Clin Cases. 2021 Dec 6;9(34):10549-10556. doi: 10.12998/wjcc.v9.i34.10549.
本文引用的文献
1
MprF-mediated daptomycin resistance.
Int J Med Microbiol. 2019 Jul;309(5):359-363. doi: 10.1016/j.ijmm.2019.05.010. Epub 2019 Jun 4.
2
Clonal Diversity and Genetic Characteristics of Methicillin-Resistant Isolates from a Tertiary Care Hospital in Japan.
Microb Drug Resist. 2019 Oct;25(8):1164-1175. doi: 10.1089/mdr.2018.0468. Epub 2019 May 20.
3
Genomic characterization of inpatient evolution of MRSA resistant to daptomycin, vancomycin and ceftaroline.
J Antimicrob Chemother. 2019 May 1;74(5):1452-1454. doi: 10.1093/jac/dkz003.
4
Effect of a Point Mutation in on Susceptibility to Daptomycin, Vancomycin, and Oxacillin in an MRSA Clinical Strain.
Front Microbiol. 2018 May 25;9:1086. doi: 10.3389/fmicb.2018.01086. eCollection 2018.
5
Vancomycin-intermediate resistance in Staphylococcus aureus.
J Glob Antimicrob Resist. 2014 Dec;2(4):213-224. doi: 10.1016/j.jgar.2014.04.006. Epub 2014 Jun 7.
6
Genomic insights into the emergence and spread of international clones of healthcare-, community- and livestock-associated meticillin-resistant Staphylococcus aureus: Blurring of the traditional definitions.
J Glob Antimicrob Resist. 2016 Sep;6:95-101. doi: 10.1016/j.jgar.2016.04.004. Epub 2016 May 17.
7
Systematic Review and Meta-Analysis of the Epidemiology of Vancomycin-Intermediate and Heterogeneous Vancomycin-Intermediate Staphylococcus aureus Isolates.
PLoS One. 2015 Aug 19;10(8):e0136082. doi: 10.1371/journal.pone.0136082. eCollection 2015.
8
First case report of vancomycin-intermediate sequence type 72 Staphylococcus aureus with nonsusceptibility to daptomycin.
BMC Infect Dis. 2014 Aug 23;14:459. doi: 10.1186/1471-2334-14-459.
9
Central nervous system infection caused by vancomycin-intermediate Staphylococcus aureus (SCCmec type IV, ST8).
J Infect Chemother. 2014 Oct;20(10):643-6. doi: 10.1016/j.jiac.2014.06.008. Epub 2014 Jul 7.
10
Genetic variation among Staphylococcus aureus strains from bovine milk and their relevance to methicillin-resistant isolates from humans.
J Clin Microbiol. 2010 Jun;48(6):2130-9. doi: 10.1128/JCM.01940-09. Epub 2010 Apr 14.
Zotero 插件